Zoekresultaten - 7 results
Factors underlying COVID-19 booster vaccine uptake among adults in Belgium
COVID-19 infection history. RESULTS: A binomial regression model was used with having received the first or second booster as outcome and age, sex, region of residence and infection history as fixed ...
Monitoring COVID-19 vaccine effectiveness against COVID-19 hospitalisation and death using electronic health registries in ≥65 years old population in six European countries, October 2021 to November 2022.
random-effects meta-analysis. RESULTS: For ≥80 years, considering unvaccinated as the reference, VE against COVID-19 hospitalisation decreased from 66.9% (95% CI: 60.1; 72.6) to 36.1% (95% CI:-27.3; 67.9) for the primary ...
Vaccine effectiveness of the second and third COVID-19 boosters in Belgium (administered during 2022 autumn campaign)
meeting the definition of immunocompromised conditions (from January 24, 2022) and to people who had received the Jcovden vaccine (Johnson&Johnson®) as a primary COVID-19 vaccination schedule (from ...
Characterisation of tetanus monoclonal antibodies as a first step towards the development of an in vitro vaccine potency immunoassay.
in these products is of utmost importance for product safety and clinical effect. Immunochemical methods that measure consistency of antigen content and quality, potentially as an indicator of potency, ...
Characterisation of diphtheria monoclonal antibodies as a first step towards the development of an in vitro vaccine potency immunoassay.
having been specifically developed as alternatives to in vivo potency tests. These methods require at least one well characterised monoclonal antibody (mAb) that is specific for the target antigen. In this ...
Regulatory issues regarding manufacture and control of vaccine adjuvants. The EU situation.
Future Development, Meeting Management, Issue Herriot,J., Vanden Bossche,G., Lausanne, Switserland (2013) Keywords: a Activity additional ALL Aluminium an Antioxidant Antioxidants application AS assessment ...
Immunogenicity and protective efficacy of DNA vaccines encoding secreted and non-secreted forms of Mycobacterium tuberculosis Ag85A.
differing potencies, as the more immunogenic DNA construct encoding a secreted form of Ag85A was protective, whereas the less immunogenic DNA construct encoding a non-secreted form of Ag85A was not. Health ...